ReleaseWire

Actinium Pharmaceuticals, Inc.(“Actinium” or “the Company”), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers initiated development of an additional antibody construct labeled with actinium-225.

CEL-SCI Corporation announced today that it has been awarded a Phase I Small Business Innovation Research (SBIR) grant in the amount of $225,000 from the National Institute of Arthritis Muscoskeletal and Skin Diseases (NIAMS), which is part of the National Institutes of Health (NIH). The grant will fund the further development of CEL-SCI’s LEAPS technology as a potential treatment for rheumatoid arthritis (RA), an autoimmune disease of the joints. According to Visiongain, the world rheumatoid arthritis drug market will generate revenues of $38.5 billion in 2017.

Global Markets Direct's, 'Thyroid Cancer - Pipeline Review, H1 2014', provides an overview of the Thyroid Cancer's therapeutic pipeline.

Global Markets Direct's, 'Vasomotor Symptoms of Menopause - Pipeline Review, H1 2014', provides an overview of the Vasomotor Symptoms of Menopause's therapeutic pipeline.

Global Markets Direct's, 'Akron Molecules AG - Product Pipeline Review - 2014', provides an overview of the Akron Molecules AG's pharmaceutical research and development focus.

Global Markets Direct's, 'Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H1 2014', provides an overview of the Cognitive Impairment Associated With Schizophrenia (CIAS)'s therapeutic pipeline.

Global Markets Direct's, 'Corticosteroid-Responsive Dermatoses - Pipeline Review, H1 2014', provides an overview of the Corticosteroid-Responsive Dermatoses's therapeutic pipeline.

The ICD Research Global Top 10 Pharmaceutical Companies: Company Guide is a crucial resource for anyone looking to gain information on the top companies in the global pharmaceutical industry. Detailed company profile and SWOT analysis information is provided for all the leading companies who are ranked in order by total annual revenues generated.

GlobalData's clinical trial report, "Chronic Spinal Cord Injury Global Clinical Trials Review, H1, 2014" provides data on the Chronic Spinal Cord Injury clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Chronic Spinal Cord Injury. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Chronic Spinal Cord Injury. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Global Markets Direct's, 'Hemorrhage - Pipeline Review, H1 2014', provides an overview of the Hemorrhage's therapeutic pipeline.

Global Markets Direct's, 'Anthrax - Pipeline Review, H1 2014', provides an overview of the Anthrax's therapeutic pipeline.

Glaucoma is a disease of the eye in which fluid pressure within the eye increases. If left untreated the patient may lose vision and even become blind. The exact etiology of optic nerve damage due to glaucoma is not fully known, but involves mechanical compression and/or decreased blood flow in the optic nerve. Based on whether the cause of the disease is unknown or known, glaucoma is divided into two types, open angle and closed angle glaucoma. Five main classes of medical treatment are currently used to lower intraocular pressure: prostaglandins, beta blockers, alpha adrenergic agonists, carbonic anhydrase inhibitors, and fixed dose combinations.

Global Markets Direct's, 'Dementia - Pipeline Review, H1 2014', provides an overview of the Dementia's therapeutic pipeline.

Global Markets Direct's, 'Retinal Degeneration - Pipeline Review, H1 2014', provides an overview of the Retinal Degeneration's therapeutic pipeline.

Global Markets Direct's, 'Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H1 2014', provides an overview of the Recurrent Head And Neck Cancer Squamous Cell Carcinoma's therapeutic pipeline.

The Mylan Pharmaceuticals, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Mylan Pharmaceuticals, Inc. since January 2007.

Global Markets Direct's, 'LEO Pharma A/S - Product Pipeline Review - 2014', provides an overview of the LEO Pharma A/S's pharmaceutical research and development focus.

Global Markets Direct's, 'Esophageal Cancer - Pipeline Review, H1 2014', provides an overview of the Esophageal Cancer's therapeutic pipeline.

PCOS, also known as Stein-Leventhal Syndrome, is one of the most common hormonal endocrine disorders in women. It is characterized by polycystic ovaries, irregular or no menstrual periods, irregular ovulation, and high levels of androgens (male hormones) in the body. The exact cause of PCOS is unknown. In PCOS, small cysts form on the ovaries, which do not produce a sufficient amount of hormone to initiate ovulation. The ovarian follicles, which are filled with fluid in preparation for ovulation, remain as cysts when ovulation does not occur. Lifestyle modifications, medication, and surgery are some of the currently available treatments for PCOS.

Global Markets Direct's, 'Xcovery, Inc. - Product Pipeline Review - 2014', provides an overview of the Xcovery, Inc.'s pharmaceutical research and development focus.

GlobalData, the industry analysis specialist, has released its latest report, "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Mexico". The report is an essential source of information and analysis on the healthcare, regulatory and reimbursement landscape in Mexico. It identifies the key trends in the country's healthcare market and provides insights into its healthcare infrastructure and demographic, regulatory and reimbursement landscape. Most importantly, the report provides valuable insights into the trends and segmentation of its pharmaceutical and medical device markets. It is built using data and information sourced from proprietary databases, secondary research, and in-house analysis by GlobalData's team of industry experts.

Global Markets Direct's, 'PIQUR Therapeutics AG - Product Pipeline Review - 2014', provides an overview of the PIQUR Therapeutics AG's pharmaceutical research and development focus.

Global Markets Direct's, 'Prostate Cancer - Pipeline Review, H1 2014', provides an overview of the Prostate Cancer's therapeutic pipeline.

GlobalData's clinical trial report, "Carpal Tunnel Syndrome Global Clinical Trials Review, H1, 2014" provides data on the Carpal Tunnel Syndrome clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Carpal Tunnel Syndrome. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Carpal Tunnel Syndrome. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

In October 2013, Teva announced that it would be cutting approximately 10% of the workforce in order to cut costs. Later that month, it announced the departure of its CEO of just 18 months, Jeremy Levin, who was forced out by Chairman Phillip Frost. This case study looks out how Teva, one of the largest pharmaceuticals companies in the world, has ended up in this position, & what the future holds